{"id":4379,"date":"2024-02-07T13:47:44","date_gmt":"2024-02-07T12:47:44","guid":{"rendered":"https:\/\/avextra.com\/?p=4379"},"modified":"2024-02-07T13:48:34","modified_gmt":"2024-02-07T12:48:34","slug":"avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors","status":"publish","type":"post","link":"https:\/\/avextra.com\/en\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/","title":{"rendered":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors"},"content":{"rendered":"<p>BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) &#8212; Avextra AG (\u201c<strong>Avextra,&nbsp;<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will support Avextra\u2019s continued expansion of its European distribution channels and accelerate clinical trials to create new evidence-based treatment options for specific indications.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color\"><strong><em><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2024\/02\/07\/2825054\/0\/en\/Avextra-AG-Announces-Closing-of-Follow-On-Capital-Raise-Supported-by-Existing-and-New-Institutional-Investors.html\" target=\"_blank\" rel=\"noreferrer noopener\">Read more<\/a><\/em><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) &#8212; Avextra AG (\u201cAvextra\u201d or the \u201cCompany\u201d), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will support Avextra\u2019s continued expansion of its European distribution channels and accelerate clinical trials to create new evidence-based treatment options for specific indications.<\/p>","protected":false},"author":1,"featured_media":4380,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"einzelbeitrag-ohne-bild","format":"standard","meta":{"inline_featured_image":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[8,9],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avextra.com\/en\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"og:description\" content=\"BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avextra AG (\u201cAvextra\u201d or the \u201cCompany\u201d), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will support Avextra\u2019s continued expansion of its European distribution channels and accelerate clinical trials to create new evidence-based treatment options for specific indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avextra.com\/en\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-07T12:47:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-07T12:48:34+00:00\" \/>\n<meta name=\"author\" content=\"MHorn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MHorn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\"},\"author\":{\"name\":\"MHorn\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43\"},\"headline\":\"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors\",\"datePublished\":\"2024-02-07T12:47:44+00:00\",\"dateModified\":\"2024-02-07T12:48:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\"},\"wordCount\":93,\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg\",\"articleSection\":[\"deutsch\",\"english\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\",\"url\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\",\"name\":\"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg\",\"datePublished\":\"2024-02-07T12:47:44+00:00\",\"dateModified\":\"2024-02-07T12:48:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg\",\"width\":1024,\"height\":685},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/avextra.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/avextra.com\/#website\",\"url\":\"https:\/\/avextra.com\/\",\"name\":\"Cannabisbasierte Arzneimittel von Avextra\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/avextra.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/avextra.com\/#organization\",\"name\":\"Avextra Pharma GmbH\",\"url\":\"https:\/\/avextra.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"caption\":\"Avextra Pharma GmbH\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/avextra-ag\/\",\"https:\/\/www.xing.com\/pages\/avextra\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43\",\"name\":\"MHorn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g\",\"caption\":\"MHorn\"},\"sameAs\":[\"https:\/\/dev.studio-horn.de\/staging\/avextra\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avextra.com\/en\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/","og_locale":"en_US","og_type":"article","og_title":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra","og_description":"BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avextra AG (\u201cAvextra\u201d or the \u201cCompany\u201d), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will support Avextra\u2019s continued expansion of its European distribution channels and accelerate clinical trials to create new evidence-based treatment options for specific indications.","og_url":"https:\/\/avextra.com\/en\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/","og_site_name":"Cannabisbasierte Arzneimittel von Avextra","article_published_time":"2024-02-07T12:47:44+00:00","article_modified_time":"2024-02-07T12:48:34+00:00","author":"MHorn","twitter_card":"summary_large_image","twitter_misc":{"Written by":"MHorn","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#article","isPartOf":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/"},"author":{"name":"MHorn","@id":"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43"},"headline":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors","datePublished":"2024-02-07T12:47:44+00:00","dateModified":"2024-02-07T12:48:34+00:00","mainEntityOfPage":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/"},"wordCount":93,"publisher":{"@id":"https:\/\/avextra.com\/#organization"},"image":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg","articleSection":["deutsch","english"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/","url":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/","name":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors - Cannabisbasierte Arzneimittel von Avextra","isPartOf":{"@id":"https:\/\/avextra.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage"},"image":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg","datePublished":"2024-02-07T12:47:44+00:00","dateModified":"2024-02-07T12:48:34+00:00","breadcrumb":{"@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#primaryimage","url":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg","width":1024,"height":685},{"@type":"BreadcrumbList","@id":"https:\/\/avextra.com\/2024\/02\/avextra-ag-announces-closing-of-follow-on-capital-raise-supported-by-existing-and-new-institutional-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/avextra.com\/"},{"@type":"ListItem","position":2,"name":"Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors"}]},{"@type":"WebSite","@id":"https:\/\/avextra.com\/#website","url":"https:\/\/avextra.com\/","name":"Cannabisbasierte Arzneimittel von Avextra","description":"","publisher":{"@id":"https:\/\/avextra.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avextra.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/avextra.com\/#organization","name":"Avextra Pharma GmbH","url":"https:\/\/avextra.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/","url":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","caption":"Avextra Pharma GmbH"},"image":{"@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/avextra-ag\/","https:\/\/www.xing.com\/pages\/avextra"]},{"@type":"Person","@id":"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43","name":"MHorn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g","caption":"MHorn"},"sameAs":["https:\/\/dev.studio-horn.de\/staging\/avextra"]}]}},"author_meta":{"display_name":"MHorn","author_link":"https:\/\/avextra.com\/en\/author\/mhorn\/"},"featured_img":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/02\/capital-raise-website-2024-02-06.svg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/avextra.com\/en\/category\/deutsch\/\" class=\"advgb-post-tax-term\">deutsch<\/a>","<a href=\"https:\/\/avextra.com\/en\/category\/english\/\" class=\"advgb-post-tax-term\">english<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">deutsch<\/span>","<span class=\"advgb-post-tax-term\">english<\/span>"]}},"comment_count":0,"relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on 7. February 2024","modified":"Updated on 7. February 2024"},"absolute_dates_time":{"created":"Posted on 7. February 2024 13:47","modified":"Updated on 7. February 2024 13:48"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4379"}],"collection":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/comments?post=4379"}],"version-history":[{"count":1,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4379\/revisions"}],"predecessor-version":[{"id":4381,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4379\/revisions\/4381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/media\/4380"}],"wp:attachment":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/media?parent=4379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/categories?post=4379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/tags?post=4379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}